Shock: Clinical Trials

118 trials for Shock, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

118 completed. 118 Phase 3, 26 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3118Completed 118
Phase 226Completed 26

Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock

Trials (filtered) newest first · largest first

All 118 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adjunctive Methylene Blue in Septic Shock
Methylene Blue, Usual Care - Septic Shock
Phase 3CompletedDr. Shannon M. Fernando502025-06-022026-03-19
Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery
Dalargin, 0.9 % NaCl - Postoperative Complications, Multiple Organ Failure
Phase 3CompletedBotkin Hospital2002025-05-132026-09-23
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
VBI-S - Septic Shock, Sepsis
Phase 3CompletedVivacelle Bio392024-08-062026-10-26
Methylene Blue for the Treatment of Septic Shock
Methylene Blue, Placebo - Septic Shock
Phase 3CompletedNorthern Jiangsu People's Hospital882024-08-052026-02-04
The Effect of Early Norepinephrine on Stroke Volume Index, Cardiac Index, Lactate, and Arterial Elastance in Pediatric Septic Shock
Norepinephrine, Ringer's Lactate - Septic Shock, Sepsis
Phase 2 / Phase 3CompletedUniversitas Indonesia422024-03-252024-06-20
Multimodal Vasopressor Strategy in Septic Shock
Simultaneous administration of vasopressors, Successive administration of vasopressors - Shock, Septic
Phase 2 / Phase 3CompletedUniversity Medical Centre Maribor792023-12-232026-03-31
Strong Albumin Solutions in Patients With Septic Shock
hyperoncotic human albumin solution, Buffered crystalloid solutions - Sepsis, Septic Shock
Phase 2 / Phase 3CompletedManchester University NHS Foundation Trust472023-11-102026-02-09
Low Dose Versus High Dose Methylene Blue in Septic Patients
Normal saline, Methylene Blue low dose, Methylene Blue high dose - Septic Shock
Phase 2 / Phase 3CompletedNational Cancer Institute, Egypt902023-08-012024-07-05
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
LTOWB, Components - Wounds and Injuries, Shock, Hemorrhagic
Phase 3CompletedUniversity of Alabama at Birmingham11002023-07-272026-09-22
The Effect Of Resuscitation Guided By Two Different Dynamic Parameters On Time To Normalization Of The Capillary Refill Time In Adult Patients With Septic Shock
Group VTI, Group IVC - Septic Shock, Resuscitation
Phase 3CompletedKasr El Aini Hospital902023-07-212025-04-29
Fibrinogen Early In Severe Trauma StudY II
Fibrinogen Concentrate, Cryoprecipitate - Trauma, Haemorrhagic Shock
Phase 3CompletedAustralian and New Zealand Intensive Care Research Centre9002022-11-212026-09-09
Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure
Norepinephrine, Lactated Ringers, Intravenous, normal saline - Respiratory Failure, Hypotension and Shock
Phase 3CompletedWright State University422022-08-092024-07-15
Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial
low titer whole blood, Standard Care - Hemorrhagic Shock, Traumatic Injury
Phase 3CompletedJason Sperry10202022-04-192026-02-12
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Routine labs - Hemorrhagic Shock, Acute Blood Loss Anemia
Phase 3CompletedLoma Linda University1992022-03-052025-08-08
Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock
Oxygen gas - Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Phase 3CompletedCentre Hospitalier Universitaire de Besancon602022-01-092024-12-30
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
cyclosporine - COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Phase 3CompletedAlexandria University662022-01-032025-05-14
Comparison of Fluid Resuscitation in Pediatric Burn Patients Using Crystalloids and With Albumin on Day Two.
5% Albumin (human) Solution, Paeds solution - Burns
Phase 2 / Phase 3CompletedKing Edward Medical University902022-01-012024-01-25
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
Levosimendan, Placebo of Levosimendan - Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Phase 3CompletedAssistance Publique - Hôpitaux de Paris2062021-08-272025-03-21
Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments
Vitamin C, Normal saline - Sepsis, Septic Shock
Phase 3CompletedUniversitaire Ziekenhuizen KU Leuven3012021-06-012024-01-25
Ivabradine for Heart Rate Control In Septic Shock
Ivabradine, Placebo - Septic Shock
Phase 3CompletedAssistance Publique - Hôpitaux de Paris4292021-02-262026-09-03

Showing 20 of 118. Sign in to see all of them.

Narrower conditions

Shock, Septic (71)  ·  Sepsis (48)  ·  Shock, Hemorrhagic (11)  ·  COVID-19 (8)  ·  Cytokine Release Syndrome (7)  ·  Multiple Organ Failure (6)  ·  Shock, Cardiogenic (6)  ·  Wounds and Injuries (6)  ·  Critical Illness (5)  ·  Pneumonia (5)  ·  Systemic Inflammatory Response Syndrome (5)  ·  Adrenal Insufficiency (4)  ·  Diabetes Insipidus (4)  ·  Hemorrhage (4)

Broader conditions

Pathological Conditions, Signs and Symptoms (118)  ·  Pathologic Processes (115)  ·  Inflammation (83)  ·  Infections (82)  ·  Systemic Inflammatory Response Syndrome (80)  ·  Sepsis (29)  ·  Respiratory Tract Diseases (19)  ·  Lung Diseases (15)  ·  Cardiovascular Diseases (14)  ·  Vascular Diseases (14)  ·  Respiratory Tract Infections (13)  ·  Coronaviridae Infections (8)  ·  Endocrine System Diseases (8)  ·  Nidovirales Infections (8)

Interventions

Saline Solution (13)  ·  Hydrocortisone (12)  ·  Sodium Chloride (10)  ·  Norepinephrine (7)  ·  Ringer's Lactate (7)  ·  Ascorbic Acid (5)  ·  Albumins (4)  ·  Methylene Blue (4)  ·  Standard of Care (4)  ·  Hydroxyethyl Starch Derivatives (3)  ·  Injections (3)  ·  Tranexamic Acid (3)  ·  Vasopressins (3)  ·  Ceftriaxone (2)  ·  Clarithromycin (2)

Sponsors

Assistance Publique - Hôpitaux de Paris (6)  ·  University of Versailles (4)  ·  Australian and New Zealand Intensive Care Research Centre (2)  ·  Beth Israel Deaconess Medical Center (2)  ·  Cairo University (2)  ·  Centre Hospitalier Universitaire de Besancon (2)  ·  Cristina Martinez (2)  ·  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (2)  ·  Frisius Medisch Centrum (2)  ·  Hospices Civils de Lyon (2)  ·  Kompetenznetz Sepsis (2)  ·  McMaster University (2)  ·  Northern Jiangsu People's Hospital (2)  ·  Novartis Pharmaceuticals (2)  ·  University Hospital, Grenoble (2)

Countries

France (33)  ·  United States (23)  ·  Germany (13)  ·  Italy (13)  ·  Canada (12)  ·  Spain (11)  ·  Belgium (10)  ·  United Kingdom (10)  ·  Australia (7)  ·  Netherlands (7)  ·  Brazil (6)  ·  Egypt (6)  ·  Austria (5)  ·  Russia (5)  ·  China (4)

Top investigators

Konrad Reinhart, MD (3)  ·  Anders Perner, MD, PhD (2)  ·  Andrea Morelli, MD (2)  ·  Didier Keh, MD (2)  ·  Djillali Annane, MD (2)  ·  Djillali Annane, MD, PhD (2)  ·  Luciano Gattinoni, MD (2)  ·  Michael W Donnino, MD (2)  ·  Pietro Caironi, MD (2)  ·  Qingquan Lyu, Master (2)  ·  Thomas Deufel, MD (2)  ·  Abdelrhman Hussein (1)  ·  Ahmed Mukhtar, Professor (1)

Results publications

PMID 23984731, PMID 24635772, PMID 25647203, PMID 33438477, PMID 38531812, PMID 40271704, PMID 10933646, PMID 16757723, PMID 16978417, PMID 17109736, PMID 17720019, PMID 18090009, PMID 18184957, PMID 18184958, PMID 18444850, PMID 18552688, PMID 19114908, PMID 19730258, PMID 19851126, PMID 20103758, PMID 20200382, PMID 20562702, PMID 20594297, PMID 20610825, PMID 20826251, PMID 20924555, PMID 21112053, PMID 21129208, PMID 21332727, PMID 21516036, PMID 21615299, PMID 21827677, PMID 21926601, PMID 21929764, PMID 22073145, PMID 22564837, PMID 22616830, PMID 22692171, PMID 22738085, PMID 23322670, PMID 23352693, PMID 23353941, PMID 23512062, PMID 23525934, PMID 24037226, PMID 24108515, PMID 24207137, PMID 24292991, PMID 24335442, PMID 24794878

NIH funding

2005 (3), 2017 (2), 2018 (2), 2019 (2), 1UG3HL157401-01A1 (1), 2009 (1), 2014 (1), K23GM083211 (1), R01HD101528 (1), R01HL043167 (1), R01HL049970 (1), U01HL077863 (1), U24HL157310 (1)